News | April 29, 2009

Long-Term Cardiovascular Study Selects OpenClinica Enterprise Management Solution

April 29, 2009 - The Abuja Heart Study, a long-term cardiovascular study involving up to 10,000 patients from multiple sites across Nigeria, will employ the OpenClinica Enterprise for electronic data capture and clinical data management.

Data is not yet available to determine the magnitude and social burden of cardiovascular disease or the distribution within the population of many countries, including Nigeria, where it is expected to become a leading cause of death within the next 10 to 15 years.

In many ways analogous to the well-known Framingham Heart Study, the Abuja Heart Study will help scientists understand the role socio-cultural and hereditary factors play in a specific population in order to adopt targeted policies for prevention and control.

OpenClinica is open source, Web-based clinical trials software for electronic data capture (EDC) and clinical data management (CDM) that reportedly facilitates study protocol configuration, data collection via electronic case report forms (eCRFs), and enables productive clinical trials management. OpenClinica supports HIPAA, 21 CFR Part 11, and other regulator guidelines and is designed as a lightweight, standards-based, extensible and modular platform.

"This study has some specific requirements for its electronic data capture and data management needs," said Study Director Uchenna Onyeachom. "We require a lightweight, standards-based, and regulatory compliant system that can function well in resource constrained settings and is intuitive to remote users with minimal training. The flexible OpenClinica technology and enterprise open source approach from Akaza provide us with these benefits and give us the necessary assurance that many years from now our study will still be run with robust and well-supported software."

Collaborators on Abuja Heart Study include the Harvard Clinical Research Institute, Byrne Healthcare, Federal Ministry of Health Nigeria and Healthsystem Plus.

For more information: http://www.openclinica.org., http://abujaheartstudy.org.

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init